EP1699472A1

EP1699472A1 - Pharmaceutical active agent against breast cancer

Info

Publication number: EP1699472A1
Application number: EP04786711A
Authority: EP
Inventors: Dirk Weickmann
Original assignee: Toximed GmbH
Current assignee: Toximed GmbH
Priority date: 2003-09-08
Filing date: 2004-09-07
Publication date: 2006-09-13
Also published as: DE112004002232D2; WO2005023276A1; DE10341307A1

Abstract

The invention relates to a pharmaceutical active agent for treating breast cancer produced by the combination of a substance obtainable from the buccal secretion of Varanidae family animals and a homeopathic substance.

Description

Active pharmaceutical ingredient against breast cancer

Everyone is responsible for the ingestion of food for the preservation of life

Living beings rely on the range of plants and animals that can be reached. But not everything is safe to eat here.

Many plants and animals use to protect their own life and for their own food, on their special organism and its special

Needs coordinated, so-called biogenic, poisons. These biogenic poisons have found their place in the interplay of different types of life in the course of long development periods.

That is why every adult wild animal still recognizes dangerous plants and poisonous animals in its natural environment.

Plants or animals can have a primarily toxic effect through the production of toxins or can only acquire secondary toxicity by ingesting toxic substances from the living or inanimate environment.

The use of these biogenic poisons began in human history as long ago as they were used to kill prey with poisoned weapons.

From the beginning, however, there were certain precautions to use these poisons safely

Basic knowledge of their treatment and effectiveness is required.

The experiments carried out further, the composition of the chemical

Decoding the build-up of biogenic poisons later led to the targeted search for certain active substances as the actual cause of the effects observed.

In particular, after the demand made by Paracelsus (1493 - 1541) to isolate the active substances from medicinal plants, which contributed to the development of latrochemistry, that is, chemistry with regard to its medical field of application, these efforts should have intensified. Above all, the art of distilling fabrics has been put to the service of research and has provided a variety of essential oils and volatiles. But the methods known at that time were insufficient for the isolation of other active substances or even for their chemical breakdown. It was not until the beginning of the 19th century that the development of technical skills in chemistry had advanced far enough to usher in the era of isolating pure active substances from biological material. First, the differences in the solubility of the investigated substances in different solvents were used to separate the active substances from the accompanying substances. The differences in the distribution behavior between two immiscible liquid phases, in the volatility and in the chemical reactivity were observed, for example with precipitation agents.

The development of chromatographic processes in the middle of the 20th century made possible a huge boom in separation technology, the way to identify active substances for combating diseases. Based on the distribution between a mobile and a stationary liquid phase, on the adsorption, the molecular sieve effects, the ion exchange, the affinity (especially of proteins) for certain chemical compounds (e.g. enzyme substrates) and the mobility of charged molecules in the electric field, a large number became new separation techniques developed

Tumors, the most dangerous and feared diseases of our time, are currently being combated in a very radical and less environmentally friendly way. The following can be used as simple, characteristic keywords: steel, radiation and chemotherapy.

On the one hand, this means that, if reasonably attainable, tumors are in principle cut out with the steel of a knife, burned by a wide range of radiation, or destroyed by so-called chemotherapy with aggressive cytostatics that also attack healthy cells. A spatial limitation of the operating area is not possible with normal treatments with a scalpel or with ionizing radiation. Healthy body cells are inevitably destroyed. The undesirable side effects of chemotherapy are well known. In contrast, however, cancer therapy that deserves its name was also attempted in a more subtle way. For this purpose, the rich treasure of nature was used. For this purpose, among other things, many highly effective substances in therapeutic doses isolated from toxic organisms are used as medicinal substances A pharmaceutical active ingredient is known from DE 199 61 141 A1, in which it has been found that components of the spider venom from spiders of the Sicaridae family can be used for the treatment of tumor diseases. Mainly, a peptide toxin from the poison of this type of spider, a further antagonistic substance obtained from the poison and / or a combination of these components are used medically. This active ingredient can be used for the treatment of tumor diseases and in parallel or in support of tumor operations and residual tumor tissue can be destroyed. In therapy, genetically modified body cells (tumor cells) can be destroyed, since the active ingredient in question recognizes the changed surface structure of such cells and kills them without complications. cannot be used pharmaceutically.

However, this known active ingredient does not work in combination in breast cancer in vivo.

Breast cancer or breast cancer is a malignant one

Breast disease. Breast cancer is the most common in the western world

Cancer in women. Breast cancer makes up about 18% of all malignancies

Diseases of women. Approximately 1 to 2 out of 1,000 women fall ill in

Germany every year on this malignant tumor.

Around 10% of all women in Germany develop this disease at some point in their lives. The focus for such an illness lies between the 45th and the 50th, as well as between the 60th and the 65th year of life. In absolute numbers, this means that 48,000 women develop breast cancer in Germany each year and around 18,000 die of it each year.

In rare cases, men are also affected by breast cancer.

With regard to the spatial distribution of the frequency of breast cancer, one can imagine a coordinate cross placed over the breast with the nipple as the center. The upper outer quadrant is particularly often affected because it also contains most of the mammary gland. The cause of breast cancer has not yet been fully elucidated. However, it is assumed that a genetic cause is jointly responsible for around 5% of women who are ill. For example, the cancer risk of people who have a relative or a first-degree relative is three times that of those in whom there is no such connection. Certain changes in the genome also seem to favor tumor development, but this has so far only been proven for a few tumor types. The initially benign proliferation of the glandular lobes of the mammary gland and the connective tissue, the so-called proliferative mastopathy, represents a further risk factor. Favorable for breast cancer development are also a high-fat food, the influence of ionizing radiation, tobacco and alcohol consumption, and the long-term use of female sex hormones.

At the slightest suspicion of breast cancer, a thorough medical examination must be carried out. In addition to the medical history and the exact scanning of both breasts, the armpits and the clavicle pits, an X-ray examination of the breast and an ultrasound examination are usually carried out. Such mammography allows the detection of microcalcifications, size and number of tumors and a distinction between benign changes. The micro-lime that accumulates in the passages of the affected part of the tissue is indirect evidence of a tumor that may still be very small.

An ultrasound examination together with a mammography, the X-ray examination, significantly increases the diagnostic certainty. If in doubt, a tissue sample (biopsy) can be taken for microscopic examination under the control of an ultrasound examination with a fine needle. Mammography and an ultrasound examination are also required immediately before an operation to precisely mark the area of the operation.

A computed tomography, a nuclear medical examination of the bones in question (bone scintigraphy) and an ultrasound examination of the liver provide indications of possibly existing daughter tumors. The result of microscopic tissue examinations (histology) provides information about the exact tumor type and the degree of the respective aggressiveness of the tumor (grading). The examination of the surgically obtained tumor and the lymph nodes allows an overview of the extent of the tumor seeding, i.e. the course of metastases.

As mentioned above, breast cancer is rare in men, but it is usually only discovered at an advanced stage. Since the fascia of the pectoral muscle is often already reached or exceeded by the tumor, the pectoral muscle must also be removed in such cases. As with women, the extent of axillary lymph node involvement plays a crucial prognostic role. Therapy and follow-up care is no different from that of a woman. However, the prognosis is more unfavorable than that of women because of the mostly advanced stage of discovery.

It is the task of the active ingredient according to the invention to enable complication-free control of breast cancer.

This object is achieved by an active ingredient which has the features of one of the independent claims 1 to 5 and is produced by a method according to claim 18.

The active substance according to the invention is essentially produced from a combination of a mixture of a homeopathic substance and a substance obtained from the purified oral secretions of one of the following animal species from the Varanidae family (monitor lizards): a) Varanus storii or dwarf monitor lizard b) Varanus gilleni or Gillen - monitor lizard c) Varanus acanthurus or barbed monitor lizard d) Varanus kingorum or king monitor lizard e) Varanus boehmei (also boehmi)

Monitor lizards form their own family in the subordination of lizards (Sauria)

(Varanidae.

There are a total of 32 different types of monitor lizards.

These live in the tropics and subtropics of Africa, Asia and Australia. 17 species of them occur in Australia alone. The smallest species are only about 20 cm long. However, most of them are large, powerful animals. The largest of them grows up to 3 meters long. It is the Komodo dragon (Varanus komodoensis). It occurs only on the island of Komodo and on a few surrounding islands in the Southeast Asian Sund archipelago.

The monitor lizards form a family close to the snakes. You have some

Body types that are very similar to snakes. One is, for example, the long, deeply split tongue. With the tip of the tongue, the monitor lizards can absorb the finest fragrances from the air. This leads them into the so-called Jacobsonian

Organ. This is a special one that sits on the palate

Olfactory organ. Thanks to their very well-developed sense of smell, the monitor lizards can easily follow the traces of their prey.

The monitor lizard's body is long and relatively wide and flat. The legs are strong and the feet have strong curved toes. The tail is long and very strong among the larger representatives. The head sits on a clearly recognizable shark and is flat, the snout is rounded. ,

In many types, the skin looks a bit too big for the body because it is on the neck and

Fuselage folds.

The lizards' scales are colored very differently. The color palette ranges from gray to muted green to brown. Some species have a pronounced pattern, such as horizontal stripes and dots.

The ways of moving the monitor lizards are extremely versatile. All monitor lizards are good swimmers and divers. They put their legs back against the body and steer with their long tail. Apart from adult Komodo dragons, all species, some of which are almost pure

Tree dwellers are good climbers. Despite their sometimes massive shape

Monitor lizards are good and fast runners.

The monitor lizards are mostly carnivores, but they also have a preference for

Eggs. Just like the snakes, they can expand their throats particularly heavily and thus devour very large chunks of food. They are all chasing

Animals that can overwhelm them. These are, for example, snakes, lizards,

Insects, small mammals, birds and even whole turtles. Monitor lizards don't despise carrion either. A Komodo dragon even hunts small deer and

Wild boars. If the monitor hunt for very large prey, it will hold onto it with its clawed toes and tear away large scraps with its teeth. This usually doesn't cause him any problems because his jaws are very strong.

Although the flesh and skins of the monitor lizard are highly valued, this is not the reason why the population of monitor lizards is shrinking worldwide. The real reason for this is rather the fat you get from them. This is mainly used to make ointments. These should help against various diseases. The lizard ointment is particularly popular in China.

According to the invention, the mouth secretion is obtained from the types of monitor lizards mentioned under a) to e). However, this is not a biogenic poison, but another biogenic agent. It is important to ensure that no secretions from the throat are used. This oral secretion is freeze-dried in amounts of 2 to 10 mg, processed under sterile conditions and dissolved in 50 ml of the homeopathic substance Tarantula D4. This mixing takes place in a homeopathic manner by shaking both substances ten times towards the center of the earth.

As is known, in homeopathy the patient receives the medication in question not in his mother tincture but in a dilution stage. The founder of homeopathy, Samuel Christian Hahnemann, made the paradoxical observation that the effect of a medicine is inversely proportional to the concentration. The more diluted the stock solution, the more effective it becomes.

The D dilution levels are made by filling 1/10 of the stock solution with 9/10 alcohol and then shaking. This gives the first dilution D1. Again take 1/10 of this dilution and shake it with 9 parts of alcohol, and you get a D2. This procedure is continued until high potencies such as D 200 finally arise. Nevertheless, they are highly effective medicines. However, in order to search for an explanatory model, one has to say goodbye to physics, which works with simple linear substance-related theses. A combination with an active ingredient described in an earlier patent application can also be used for the use of the active ingredient according to the invention when breast cancer begins to develop.

Optionally, the active ingredient according to the invention can be an antagonistic or synergistic and / or penetrating substance to the respective oral secretion from the. Oral secretions, of the species concerned.

The antagonistic or synergistic substance is preferably a phospholipase or a hyaluronidase or a combination of both substances.

It is further preferred that the antagonistic or synergistic substance is a mixture of the phospholipases and hyaluronidases and / or toxins present in other species.

The oral secretion and the substance which is antagonistic and / or synergistically active for this purpose are preferably obtained by a fractionation process from the total cocktail of the oral secretion, and it is further preferred that the pharmaceutical active substance contains an oral secretion and a substance which has an antagonistic or synergistic effect which consists of different fractions. As a result, the effect of the pharmaceutical active ingredient can advantageously be tailored to the type of polyp or ulcer to be treated.

The oral secretion and the substance having an antagonistic and / or synergistic effect can be obtained by known fractionation processes for the separation of proteins from the mouth saliva. It is preferred that the substances obtained and the substance having an antagonistic or synergistic effect on them are obtained by gel chromatography, HPC, affinity chromatography and / or ion exchange chromatography.

It is also preferred that the oral secretion is present as an active pharmaceutical ingredient in such an amount that the active ingredient has a destructive effect on sick cells. Furthermore, the required proportions are chosen so that the active ingredient according to the invention has no or only a slight toxic effect in the patient to be treated. Of course, the amounts of the active pharmaceutical ingredients must also be matched to the type of illness to be treated and the physical, possibly also psychological, circumstances of the respective patient. The preliminary tests required for such a coordination are to be carried out by the person skilled in the art in the context of animal tests and / or ethically justifiable tests on the patient on the basis of his specialist knowledge and ability.

Also preferred is an active pharmaceutical ingredient in which the amount of. Oral secretions, and the substance antagonistic or synergistic acting for this purpose, a further amount of homeopathic substance, enzymes and antagonistic or synergistic substance is added, which is selected depending on the disease to be treated.

It is further preferred that the pharmaceutical active ingredient according to the invention contains conventional carriers and auxiliary substances, such as antibiotics, antifungals, antituberculotics, agents against parasites, cytostatics, amino acids, enzymes which promote wound healing and / or mitotic inhibitors. Preferred are penicillin / streptomycin, polymyxin / genetic mycin (5%), mitopodocide, vinca rosea alkaloids, bromelaina or bromelains.

The oral secretion and the antagonistic or synergistic substance are used in combination with the homeopathic substance in the pharmaceutical active ingredient according to the invention. However, it is also possible to use the individual substances in active pharmaceutical ingredients and to make the special effects of the individual substances available for therapeutic use.

It is also possible to produce the described active substances chemically or synthetically or in recombined form using genetic engineering methods. As is usual with chemical substances, the present invention also includes derivatives and salts of the substances provided according to the invention. For example the purified oral secretion comprises one or more additions, substitutions and / or deletions of amino acids, it of course having to be ensured that the medicinal effect according to the invention is retained. The active ingredient described is obtained by methods customary in chemical process engineering. These include in particular fractionation processes; however, other methods can also be used, for example immunological methods to obtain the desired substances from the. Oral secretions to get out

In the method according to the invention, it is preferred that the oral secretion is homogenized before the fractionation, and it is further preferred that the fractions are freeze-dried or frozen and preferably lyophilized before further processing.

In order to prevent unwanted cell destruction, according to the invention, depending on the type and size of the cell area to be treated, a comparison can be made with respect to absolute and relative amounts of the components of the active ingredient according to the invention in vitro on living human cells (healthy and sick) of the tissue type to be treated. Attention to the tendency to spread is of the greatest importance. This can be determined in preliminary tests in comparison to the tissue strength to the tissue surrounding the focus of the disease.

The mode of action of the oral secretion or individual substances separated therefrom by column chromatography and / or characterized by the molecular weight can be carried out by testing them in corresponding healthy and diseased human cell lines.

According to the present invention, the substances used preferably originate from the same organism as the substances which have an antagonistic or synergistic effect and / or further active substances optionally present. In this way, the effective interaction or counterplay of these substances developed by nature can be exploited. The pharmaceutical active substances according to the invention can be produced in such a way that first a raw oral secretion mixture is obtained by methods known per se and fractionation of the raw mixture is carried out by fractionation methods likewise known per se for the separation of proteins. This serves the purpose of the enzymes and the to obtain antagonistic or synergistic substances for this purpose in as separate a form as possible or in separate fractions. Various fractions can then be combined to produce a pharmaceutical active ingredient, or individual fractions can be combined with substances originating from other organisms or substances having an antagonistic or synergistic effect. Individual fractions can also be used to produce an active pharmaceutical ingredient. Hyaluronidases from snake venoms, for example from cobra venoms, can preferably be used as antagonistic substances. This can be combined with one or more fractions from substances obtained from monitor lizards of the types mentioned under a) to e).

It is also possible to combine the fractions with other suitable active ingredients and / or with carriers and auxiliaries customary in pharmacy to produce pharmaceutical active ingredients according to the invention.

For the production of the pharmaceutical active substances according to the invention, e.g. by column chromatographic purification specific components (necrotic and cytotoxic substances) as well as natural antagonistic substances (stop substances) of the phospholipase and hyaluronidase type are selected.

The preparation of an active ingredient according to the invention in a small amount is described below purely by way of example. The information given shows only by way of example the quantitative ratio of the substances used. In the oral secretion obtained from the animal species mentioned, portions of 2 to 10 mg are freeze-dried, processed under sterile conditions, and dissolved in 50 ml of Tarantula D 4, the solution being shaken ten times to the center of the earth.

The entire freeze-dried mouth extract taken from a sterile cotton swab is used for each animal.

Every monitor lizard can be removed every 4 to 6 weeks without stress.

You need 10 to 20 approvals for a stock solution approach.

To prepare an administration dose, 0.9% NaCl solution in vials with 50 ml content is preferably used.

30 ml of NaCl solution are drawn off and 25 ml of the active ingredient solution are added.

Patients were injected with 2.5 ml of the active ingredient according to the invention for 5 days, then 3 ml every 2 days, into the upper arms.

Here, the tumor process was observed using tumor markers and LSA tests, as well as using imaging techniques.

Tumor regression was observed after 2 to 50 months of treatment. The patients were without chemotherapy and without radiation, but they had previously undergone surgery.

Vitamin C-free selenium supplements are suitable as accompanying therapy.

Claims

Expectations

Claim 1: Pharmaceutical active ingredient for the treatment of breast cancer, containing in a pharmaceutically effective amount: a) at least one purified oral secretion, and b) at least one homeopathic substance, and c) at least one enzyme, and d) at least one substance which has an antagonistic effect or synergistic substance, at least the oral secretion, or at least the enzyme and optionally the antagonistic or synergistic substance and / or the penetrating substance, originating from the oral secretion of animals of the species Varanus storii.

Claim 2: Pharmaceutical active ingredient for the treatment of breast cancer, containing in a pharmaceutically effective amount: a) at least one purified oral secretion, and b) at least one homeopathic substance, and c) at least one enzyme, and d) at least one substance which has an antagonistic effect or synergistic substance, at least the oral secretion, or at least the enzyme and optionally the antagonistic or synergistic substance and / or the penetrating substance, originating from the oral secretion of animals of the species Varanus gilleni. Claim 3: Pharmaceutical active ingredient for the treatment of breast cancer, containing in a pharmaceutically effective amount: a) at least one purified oral secretion, and b) at least one homeopathic substance, and c) at least one enzyme, and d) at least one substance which has an antagonistic effect or synergistic substance, wherein at least the oral secretion, or at least the enzyme and optionally the antagonistic or synergistic substance and / or the penetrating substance originate from the oral secretion of animals of the species Varanus acanthurus.

Claim 4: Pharmaceutical active ingredient for the treatment of breast cancer, comprising in a pharmaceutically effective amount: a) at least one purified oral secretion, and b) at least one homeopathic substance, and c) at least one enzyme, and d) at least one substance which has an antagonistic effect or synergistic substance, at least the oral secretion, or at least the enzyme and optionally the antagonistic or synergistic substance and / or the penetrating substance derived from the oral secretion of animals of the species Varanus kingorum.

Claim 5: Pharmaceutical active ingredient for the treatment of breast cancer, containing in a pharmaceutically effective amount: a) at least one purified oral secretion, and b) at least one homeopathic substance, and c) at least one enzyme, and d) at least one substance which has an antagonistic effect or synergistic substance, at least the oral secretion, or at least the enzyme and optionally the antagonistic or synergistic substance and / or the penetrating substance derived from the oral secretion of animals of the species Varanus boehmi.

Claim 6: active pharmaceutical ingredient according to one of claims 1 to 5, characterized in that the homeopathic substance is Tarantula D4.

Claim 7: Active pharmaceutical ingredient according to one of the preceding claims, characterized in that the antagonistically active substance or the synergistically active substance and / or the penetrating substance originate from a different organism than from one of the types mentioned under Claims 1 to 5.

Claim 8: active pharmaceutical ingredient according to one of the preceding claims, characterized in that an enzyme and / or the antagonistically active substance or the synergistically active substance and / or the penetrating substance Phospholipase or a hyaluronidase or a combination of both substances.

Claim 9: Active pharmaceutical ingredient according to one of the preceding claims, characterized in that an enzyme and / or the antagonistically active substance, or the synergistically active substance and / or the penetrating substance were obtained by a fractionation process from the respective oral secretions.

Claim 10: Active pharmaceutical ingredient according to one of the preceding claims, characterized in that an enzyme and / or the antagonistically active substance, or the synergistically active substance and / or the penetrating substance by gel chromatography, HPLC, affinity chromatography and / or ion exchange chromatography from the respective Oral secretions were obtained.

Claim 11: Active pharmaceutical ingredient according to one of the preceding claims, characterized in that an enzyme and / or the antagonistically active substance, or the synergistically active substance and / or the penetrating substance were obtained as follows: By using a column with an inner diameter of 1, 5 cm and a height of 50 cm, which tapers to 1.5 mm at the bottom and which contains 20 ml of an AcA 34 chromatographic gel, matrix: 3% acrylamide 4% agarose, fractionation range 20 to 350 kDa, cut-off limit 750 kDa, bead diameter 60 - 140 µm is filled. The corresponding poison in 0.25M Tris / HCl, pH 6.5 to 7.3, and 1.92M glycine in distilled, deionized water was applied to the gel in a homogeneous state. When the poison solution has passed through the gel and 165 ml of a solution of 0.25 M Tris / HCl, pH 6.5 to 7.3, and 1.92 M glycine in distilled, deionized water have been applied and the first 15 ml of the run discarded and collected in 4 ml fractions, the peptide toxins are in fractions 1, 2, 4, 7, 9 and 10 and the antagonistic substances or the synergistic substances and / or the penetrating substances are in fractions 3.5 , 6,8,11 and 12 ..

Claim 12: Active pharmaceutical ingredient according to one of the preceding claims, characterized in that it contains an enzyme and / or a substance having an antagonistic effect thereon, or a substance having a synergistic effect, which originate from different fractions of the respective oral secretions.

Claim 13: active pharmaceutical ingredient according to one of the preceding claims, characterized in that the amount is selected such that a spatial and / or time-controlled spread in the tissue is ensured.

Claim 14: Pharmaceutical active ingredient according to one of the preceding claims, characterized in that the amount of homeopathic substance, as well as oral secretion, and antagonistic substance or synergistic substance and / or penetrating substance is selected depending on the tissue to be treated. Claim 15: Pharmaceutical active substance according to one of the preceding claims, characterized in that it contains conventional carriers and auxiliary substances and / or further active substances.

Claim 16: Pharmaceutical active substance according to one of the preceding claims, characterized in that it is isotonic solutions, protein solutions, amino acid solutions and / or germicidal solutions, preferably Ringer's solution, 0.9% NaCl solution, human albumin solution, as usual carriers and auxiliaries and / or glutamine solution, and that it contains antibiotics, antifungals, antituberculotics, agents against parasites, amino acids, enzymes which favor wound treatment, mitotic inhibitors and / or cytostatics as further active ingredients.

Claim 17: Pharmaceutical active substance according to one of the preceding claims, characterized in that a derivative, the oral secretion, or the enzyme, and / or the antagonistic substance or the synergistic substance and / or the through substance is contained in the active substance and / or the oral secretion, or the enzyme, and / or the substance which has an antagonistic action or the synergistic substance and / or the penetrating substance is produced chemically-synthetically or by recombinant biotechnological methods and they correspond in their action to the active ingredients contained in the oral secretion, the respective animals or to the substances having an antagonistic or synergistic effect and / or penetrating substances and derivatives thereof.

Claim 18: Method for the production of a pharmaceutical active substance for the treatment of breast cancer, containing in a pharmaceutically effective amount at least one homeopathic substance, an enzyme or an oral secretion, as well as at least one substance having an antagonistic or synergistic effect and / or at least one penetrating substance , wherein the enzyme or the oral secretion comes from animals according to any one of claims 1 to 5 and optionally the substance having an antagonistic effect or the synergistic acting substance and / or the penetrating substance comes from the oral secretion of animals according to any one of claims 1 to 5, with the following steps: obtaining oral secretions, from these animals, and an enzyme by methods known per se, and fractionating the mixture around the enzyme and, optionally, the substance which acts antagonistically or synergistically and / or the penetrating substance and optionally further substances in as much as possible to obtain separate fractions; Combination of different fractions of the enzyme with fractions which contain antagonistic or synergistic substances and / or penetrating substances for this purpose, or with antagonistic or synergistic substances and / or penetrating substances originating from other organisms, in order to obtain a pharmaceutically active substance. Claim 19: Method according to claim 18, characterized in that Tarantula D4 is used as the homeopathic substance.

Claim 20: Method according to one of claims 8 or 19, characterized in that the oral secretion is obtained in a gentle manner from preferably female animals.

Claim 21: Method according to one of claims 8 to 20, characterized in that the fraction is frozen and further preferably lyophilized before further processing to a pharmaceutically active substance.